Decreased Serum Albumin Predicts Bleeding Events in Patients on Antiplatelet Therapy After Percutaneous Coronary Intervention
Background:Antiplatelet therapy (APT) after percutaneous coronary intervention (PCI) prevents ischemic events with increased risk of bleeding. Little is known about the relationship between hypoalbuminemia and bleeding risk in patients receiving APT after PCI. This study investigated the association...
Saved in:
Published in | Circulation Journal Vol. 81; no. 7; pp. 999 - 1005 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Japan
The Japanese Circulation Society
2017
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background:Antiplatelet therapy (APT) after percutaneous coronary intervention (PCI) prevents ischemic events with increased risk of bleeding. Little is known about the relationship between hypoalbuminemia and bleeding risk in patients receiving APT after PCI. This study investigated the association between serum albumin level and bleeding events in this population.Methods and Results:We enrolled 438 consecutive patients who were prescribed dual APT (DAPT; aspirin and thienopyridine) beyond 1 month after successful PCI without adverse events. The patients were divided into 3 groups according to serum albumin tertile: tertile 1, ≤3.7 g/dL; tertile 2, 3.8–4.1 g/dL; and tertile 3, ≥4.2 g/dL. Adverse bleeding events were defined as Bleeding Academic Research Consortium criteria types 2, 3, and 5. During the median follow-up of 29.5 months, a total of 30 adverse bleeding events were observed. Median duration of DAPT was 14 months. The tertile 1 group had the highest risk of adverse bleeding events (event-free rate, 83.1%, 94.3% and 95.8%, respectively; P<0.001). On Cox proportional hazards modeling, serum albumin independently predicted adverse bleeding events (HR, 0.10, 95% CI: 0.027–0.39, P=0.001, for tertile 3 vs. tertile 1).Conclusions:Decreased serum albumin predicted bleeding events in patients with APT after PCI. |
---|---|
AbstractList | Background:Antiplatelet therapy (APT) after percutaneous coronary intervention (PCI) prevents ischemic events with increased risk of bleeding. Little is known about the relationship between hypoalbuminemia and bleeding risk in patients receiving APT after PCI. This study investigated the association between serum albumin level and bleeding events in this population.Methods and Results:We enrolled 438 consecutive patients who were prescribed dual APT (DAPT; aspirin and thienopyridine) beyond 1 month after successful PCI without adverse events. The patients were divided into 3 groups according to serum albumin tertile: tertile 1, ≤3.7 g/dL; tertile 2, 3.8–4.1 g/dL; and tertile 3, ≥4.2 g/dL. Adverse bleeding events were defined as Bleeding Academic Research Consortium criteria types 2, 3, and 5. During the median follow-up of 29.5 months, a total of 30 adverse bleeding events were observed. Median duration of DAPT was 14 months. The tertile 1 group had the highest risk of adverse bleeding events (event-free rate, 83.1%, 94.3% and 95.8%, respectively; P<0.001). On Cox proportional hazards modeling, serum albumin independently predicted adverse bleeding events (HR, 0.10, 95% CI: 0.027–0.39, P=0.001, for tertile 3 vs. tertile 1).Conclusions:Decreased serum albumin predicted bleeding events in patients with APT after PCI. Antiplatelet therapy (APT) after percutaneous coronary intervention (PCI) prevents ischemic events with increased risk of bleeding. Little is known about the relationship between hypoalbuminemia and bleeding risk in patients receiving APT after PCI. This study investigated the association between serum albumin level and bleeding events in this population.Methods and Results:We enrolled 438 consecutive patients who were prescribed dual APT (DAPT; aspirin and thienopyridine) beyond 1 month after successful PCI without adverse events. The patients were divided into 3 groups according to serum albumin tertile: tertile 1, ≤3.7 g/dL; tertile 2, 3.8-4.1 g/dL; and tertile 3, ≥4.2 g/dL. Adverse bleeding events were defined as Bleeding Academic Research Consortium criteria types 2, 3, and 5. During the median follow-up of 29.5 months, a total of 30 adverse bleeding events were observed. Median duration of DAPT was 14 months. The tertile 1 group had the highest risk of adverse bleeding events (event-free rate, 83.1%, 94.3% and 95.8%, respectively; P<0.001). On Cox proportional hazards modeling, serum albumin independently predicted adverse bleeding events (HR, 0.10, 95% CI: 0.027-0.39, P=0.001, for tertile 3 vs. tertile 1). Decreased serum albumin predicted bleeding events in patients with APT after PCI. BACKGROUNDAntiplatelet therapy (APT) after percutaneous coronary intervention (PCI) prevents ischemic events with increased risk of bleeding. Little is known about the relationship between hypoalbuminemia and bleeding risk in patients receiving APT after PCI. This study investigated the association between serum albumin level and bleeding events in this population.Methods and Results:We enrolled 438 consecutive patients who were prescribed dual APT (DAPT; aspirin and thienopyridine) beyond 1 month after successful PCI without adverse events. The patients were divided into 3 groups according to serum albumin tertile: tertile 1, ≤3.7 g/dL; tertile 2, 3.8-4.1 g/dL; and tertile 3, ≥4.2 g/dL. Adverse bleeding events were defined as Bleeding Academic Research Consortium criteria types 2, 3, and 5. During the median follow-up of 29.5 months, a total of 30 adverse bleeding events were observed. Median duration of DAPT was 14 months. The tertile 1 group had the highest risk of adverse bleeding events (event-free rate, 83.1%, 94.3% and 95.8%, respectively; P<0.001). On Cox proportional hazards modeling, serum albumin independently predicted adverse bleeding events (HR, 0.10, 95% CI: 0.027-0.39, P=0.001, for tertile 3 vs. tertile 1).CONCLUSIONSDecreased serum albumin predicted bleeding events in patients with APT after PCI. |
Author | Ishii, Hideki Sumi, Takuya Aoki, Toshijiro Tatami, Yosuke Yamamoto, Dai Kawamiya, Toshiki Hirayama, Kenshi Shibata, Yohei Kawashima, Kazuhiro Kunimura, Ayako Harada, Kazuhiro Suzuki, Susumu Negishi, Yosuke Murohara, Toyoaki |
Author_xml | – sequence: 1 fullname: Tatami, Yosuke organization: Department of Cardiology, Nagoya University Graduate School of Medicine – sequence: 2 fullname: Ishii, Hideki organization: Department of Cardiology, Nagoya University Graduate School of Medicine – sequence: 3 fullname: Aoki, Toshijiro organization: Department of Cardiology, Nagoya University Graduate School of Medicine – sequence: 4 fullname: Harada, Kazuhiro organization: Department of Cardiology, Nagoya University Graduate School of Medicine – sequence: 5 fullname: Hirayama, Kenshi organization: Department of Cardiology, Nagoya University Graduate School of Medicine – sequence: 6 fullname: Shibata, Yohei organization: Department of Cardiology, Nagoya University Graduate School of Medicine – sequence: 7 fullname: Sumi, Takuya organization: Department of Cardiology, Nagoya University Graduate School of Medicine – sequence: 8 fullname: Negishi, Yosuke organization: Department of Cardiology, Nagoya University Graduate School of Medicine – sequence: 9 fullname: Kawashima, Kazuhiro organization: Department of Cardiology, Nagoya University Graduate School of Medicine – sequence: 10 fullname: Kunimura, Ayako organization: Department of Cardiology, Nagoya University Graduate School of Medicine – sequence: 11 fullname: Kawamiya, Toshiki organization: Department of Cardiology, Nagoya University Graduate School of Medicine – sequence: 12 fullname: Yamamoto, Dai organization: Department of Cardiology, Nagoya University Graduate School of Medicine – sequence: 13 fullname: Suzuki, Susumu organization: Department of Cardiology, Nagoya University Graduate School of Medicine – sequence: 14 fullname: Murohara, Toyoaki organization: Department of Cardiology, Nagoya University Graduate School of Medicine |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28344205$$D View this record in MEDLINE/PubMed |
BookMark | eNpFkElP5DAQha0RiG24z2nkI5eAtyTOsQm7kECCOVuOXQG3EqfHdpA48N9Juhu4VL1SffVUeodoxw8eEPpDySllOT8zLpjlaX2X0TIjhOa_0AHlosyEZGRnrYuskoLvo8MYl4SwiuTVHtpnkgvBSH6APi7ABNARLH6CMPZ40TVj7zx-DGCdSRGfdzAp_4Iv38BP87zTya314PHCJ7fqdIIOEn5-haBX73jRJgj4EYIZk_YwjBHXQxi8Du_41k-72coN_jfabXUX4Xjbj9C_q8vn-ia7f7i-rRf3mSkYSxlIAtaUvGUVmEbnrRSNsK1tDIOSklJXkgLV3GgBljZ5Ia21omDQcAHCan6ETja-qzD8HyEm1btooOs2zykqJRWiFLyYULJBTRhiDNCqVXD99LiiRM2hq3Xoqr5TtFRz6NPJ36372PRgvw--Up6Aqw2wjEm_wDegQ3Kmg62jpKqcy4_zD_CqgwLPPwH2-506 |
CitedBy_id | crossref_primary_10_1016_j_amjcard_2023_02_027 crossref_primary_10_5551_jat_47654 crossref_primary_10_1016_j_amjcard_2021_10_043 crossref_primary_10_1016_j_ijcard_2021_11_046 crossref_primary_10_1016_j_numecd_2022_01_016 crossref_primary_10_1111_eci_13789 crossref_primary_10_3390_ijms24087375 crossref_primary_10_2139_ssrn_3935603 crossref_primary_10_1007_s11239_020_02092_w crossref_primary_10_1007_s11239_018_1707_1 crossref_primary_10_1016_j_jjcc_2018_12_009 crossref_primary_10_1016_j_injury_2017_08_060 crossref_primary_10_1016_j_jjcc_2018_10_013 crossref_primary_10_1016_j_ijcard_2020_10_015 |
Cites_doi | 10.1001/jama.1994.03520130074036 10.1056/NEJMoa1409312 10.2307/2531595 10.1161/CIRCULATIONAHA.110.009449 10.3945/an.111.001800 10.1161/CIRCULATIONAHA.111.071589 10.1016/j.jacc.2014.11.008 10.1161/01.CIR.0000042673.07632.76 10.2215/CJN.09260913 10.1002/sim.2929 10.1097/MCA.0b013e32835c46fd 10.1093/oxfordjournals.aje.a010232 10.1111/j.1523-1755.2004.00520.x 10.1146/annurev.med.51.1.245 10.1111/j.0894-0959.2004.17603.x 10.1111/j.1523-1755.2005.00455.x 10.1016/j.jacc.2012.06.043 10.1016/S0140-6736(14)62052-3 10.1253/circj.CJ-09-0498 10.1111/j.1532-5415.1999.tb01583.x 10.1016/j.euje.2005.12.014 10.1055/s-0041-111499 10.1001/jama.2016.3775 10.1016/j.jacc.2015.01.039 10.1016/j.ajem.2016.06.049 10.1111/j.1532-5415.2005.53369.x 10.1053/j.ajkd.2008.12.034 10.1016/j.ahj.2007.11.043 10.1016/j.mam.2011.12.002 10.1046/j.1365-2141.1996.5101050.x 10.1177/014860719702100281 |
ContentType | Journal Article |
Copyright | 2017 THE JAPANESE CIRCULATION SOCIETY |
Copyright_xml | – notice: 2017 THE JAPANESE CIRCULATION SOCIETY |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1253/circj.CJ-17-0015 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1347-4820 |
EndPage | 1005 |
ExternalDocumentID | 10_1253_circj_CJ_17_0015 28344205 article_circj_81_7_81_CJ_17_0015_article_char_en |
Genre | Clinical Trial Journal Article Observational Study |
GroupedDBID | --- .55 29B 2WC 53G 5GY 5RE 6J9 AAUGY ACGFO ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS BAWUL CS3 DIK DU5 E3Z EBS EJD F5P GX1 JSF JSH KQ8 M~E OK1 P2P RJT RNS RZJ TR2 W2D X7M XSB ZXP CGR CUY CVF ECM EIF NPM .GJ 3O- AAYXX CITATION RYR TKC 7X8 |
ID | FETCH-LOGICAL-c622t-e80edc73f29ecba5f84b4dfdbc2e7107a981e1a3ca4ed1b568ddd462eb34e4da3 |
ISSN | 1346-9843 |
IngestDate | Sun May 12 02:42:38 EDT 2024 Fri Aug 23 02:59:08 EDT 2024 Fri May 24 00:03:53 EDT 2024 Thu Aug 17 20:29:17 EDT 2023 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 7 |
Keywords | Antiplatelet therapy Albumin Bleeding event Percutaneous coronary intervention |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c622t-e80edc73f29ecba5f84b4dfdbc2e7107a981e1a3ca4ed1b568ddd462eb34e4da3 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 |
OpenAccessLink | https://www.jstage.jst.go.jp/article/circj/81/7/81_CJ-17-0015/_article/-char/en |
PMID | 28344205 |
PQID | 1881447436 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_1881447436 crossref_primary_10_1253_circj_CJ_17_0015 pubmed_primary_28344205 jstage_primary_article_circj_81_7_81_CJ_17_0015_article_char_en |
PublicationCentury | 2000 |
PublicationDate | 2017-00-00 |
PublicationDateYYYYMMDD | 2017-01-01 |
PublicationDate_xml | – year: 2017 text: 2017-00-00 |
PublicationDecade | 2010 |
PublicationPlace | Japan |
PublicationPlace_xml | – name: Japan |
PublicationTitle | Circulation Journal |
PublicationTitleAlternate | Circ J |
PublicationYear | 2017 |
Publisher | The Japanese Circulation Society |
Publisher_xml | – name: The Japanese Circulation Society |
References | 4. Sullivan DH, Roberson PK, Bopp MM. Hypoalbuminemia 3 months after hospital discharge: Significance for long-term survival. J Am Geriatr Soc 2005; 53: 1222–1226. 17. Kim BK, Hong MK, Shin DH, Nam CM, Kim JS, Ko YG, et al; RESET Investigators. A new strategy for discontinuation of dual antiplatelet therapy: The RESET Trial (Real Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol 2012; 60: 1340–1348. 28. Kim BC, Cheon JH, Kim TI, Kim WH. Risk factors and the role of bedside colonoscopy for lower gastrointestinal hemorrhage in critically ill patients. Hepatogastroenterology 2008; 55: 2108–2111. 15. Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157–172. 8. Liang CC, Wang SM, Kuo HL, Chang CT, Liu JH, Lin HH, et al. Upper gastrointestinal bleeding in patients with CKD. Clin J Am Soc Nephrol 2014; 9: 1354–1359. 24. Ershler WB, Keller ET. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med 2000; 51: 245–270. 3. Corti MC, Guralnik JM, Salive ME, Sorkin JD. Serum albumin level and physical disability as predictors of mortality in older persons. JAMA 1994; 272: 1036–1042. 29. Oduncu V, Erkol A, Karabay CY, Kurt M, Akgün T, Bulut M, et al. The prognostic value of serum albumin levels on admission in patients with acute ST-segment elevation myocardial infarction undergoing a primary percutaneous coronary intervention. Coron Artery Dis 2013; 24: 88–94. 25. Ferrucci L, Harris TB, Guralnik JM, Tracy RP, Corti MC, Cohen HJ, et al. Serum IL-6 level and the development of disability in older persons. J Am Geriatr Soc 1999; 47: 639–646. 2. Yeh RW, Secemsky EA, Kereiakes DJ, Normand ST, Gershlick AH, Cohen DJ, et al; DAPT Study Investigators. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA 2016; 315: 1735–1749. 5. Menon V, Greene T, Wang X, Pereira AA, Marcovina SM, Beck GJ, et al. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int 2005; 68: 766–772. 31. Ben-Zvi GT, Tidman MJ. Be vigilant for scurvy in high-risk groups. Practitioner 2012; 256: 23–25. 18. Gilard M, Barragan P, Noryani AA, Noor HA, Majwal T, Hovasse T, et al. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: The randomized, multicenter ITALIC trial. J Am Coll Cardiol 2015; 65: 777–786. 19. Elmariah S, Mauri L, Doros G, Galper BZ, O’Neill KE, Steg PG, et al. Extended duration dual antiplatelet therapy and mortality: A systematic review and meta-analysis. Lancet 2015; 385: 792–798. 22. Fanali G, di Masi A, Trezza V, Marino M, Fasano M, Ascenzi P. Human serum albumin: From bench to bedside. Mol Aspects Med 2012; 33: 209–290. 13. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: A consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123: 2736–2747. 9. Cheng HC, Wu CT, Chen WY, Yang EH, Chen PJ, Sheu BS. Risk factors determining the need for second-look endoscopy for peptic ulcer bleeding after endoscopic hemostasis and proton pump inhibitor infusion. Endosc Int Open 2016; 4: E255–E262. 10. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al; Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982–992. 33. Chakraverty R, Davidson S, Peggs K, Stross P, Garrard C, Littlewood TJ. The incidence and cause of coagulopathies in an intensive care population. Br J Haematol 1996; 93: 460–463. 27. Zhang Q, Lei YX, Wang Q, Jin YP, Fu RL, Geng HH, et al. Serum albumin level is associated with the recurrence of acute ischemic stroke. Am J Emerg Med 2016; 34: 1812–1816. 6. Djoussé L, Rothman KJ, Cupples LA, Levy D, Ellison RC. Serum albumin and risk of myocardial infarction and all-cause mortality in the Framingham Offspring Study. Circulation 2002; 106: 2919–2924. 16. Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, et al; Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: A randomized multicenter trial. Circulation 2012; 125: 2015–2026. 20. Giustino G, Baber U, Sartori S, Mehran R, Mastoris I, Kini AS, et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation: A systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol 2015; 65: 1298–1310. 23. Kaysen GA, Dubin JA, Müller HG, Rosales L, Levin NW, Mitch WE; HEMO Study Group NIDDK. Inflammation and reduced albumin synthesis associated with stable decline in serum albumin in hemodialysis patients. Kidney Int 2004; 65: 1408–1415. 14. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 1988; 44: 837–845. 7. Horwich TB, Kalantar-Zadeh K, MacLellan RW, Fonarow GC. Albumin levels predict survival in patients with systolic heart failure. Am Heart J 2008; 155: 883–889. 32. Shearer MJ, Fu X, Booth SL. Vitamin K nutrition, metabolism, and requirements: Current concepts and future research. Adv Nutr 2012; 3: 182–195. 30. Rady MY, Ryan T, Starr NJ. Clinical characteristics of preoperative hypoalbuminemia predict outcome of cardiovascular surgery. JPEN J Parenter Enteral Nutr 1997; 21: 81–90. 21. Don BR, Kaysen G. Serum albumin: Relationship to inflammation and nutrition. Semin Dial 2004; 17: 432–437. 12. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al; American Society of Echocardiography’s Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echocardiography Committee; American Heart Association; European Association of Echocardiography, European Society of Cardiology. Recommendations for chamber quantification. Eur J Echocardiogr 2006; 7: 79–108. 26. Nelson JJ, Liao D, Sharrett AR, Folsom AR, Chambless LE, Shahar E, et al. Serum albumin level as a predictor of incident coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 2000; 151: 468–477. 1. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, et al; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014; 371: 2155–2166. 11. Kinugasa Y, Kato M, Sugihara S, Hirai M, Kotani K, Ishida K, et al. A simple risk score to predict in-hospital death of elderly patients with acute decompensated heart failure: Hypoalbuminemia as an additional prognostic factor. Circ J 2009; 73: 2276–2281. 22 23 24 25 26 27 28 29 30 31 10 32 11 33 12 13 14 15 16 17 18 19 1 2 3 4 5 6 7 8 9 20 21 |
References_xml | – ident: 3 doi: 10.1001/jama.1994.03520130074036 – ident: 1 doi: 10.1056/NEJMoa1409312 – ident: 14 doi: 10.2307/2531595 – ident: 13 doi: 10.1161/CIRCULATIONAHA.110.009449 – ident: 32 doi: 10.3945/an.111.001800 – ident: 16 doi: 10.1161/CIRCULATIONAHA.111.071589 – ident: 18 doi: 10.1016/j.jacc.2014.11.008 – ident: 6 doi: 10.1161/01.CIR.0000042673.07632.76 – ident: 8 doi: 10.2215/CJN.09260913 – ident: 15 doi: 10.1002/sim.2929 – ident: 29 doi: 10.1097/MCA.0b013e32835c46fd – ident: 31 – ident: 26 doi: 10.1093/oxfordjournals.aje.a010232 – ident: 23 doi: 10.1111/j.1523-1755.2004.00520.x – ident: 24 doi: 10.1146/annurev.med.51.1.245 – ident: 28 – ident: 21 doi: 10.1111/j.0894-0959.2004.17603.x – ident: 5 doi: 10.1111/j.1523-1755.2005.00455.x – ident: 17 doi: 10.1016/j.jacc.2012.06.043 – ident: 19 doi: 10.1016/S0140-6736(14)62052-3 – ident: 11 doi: 10.1253/circj.CJ-09-0498 – ident: 25 doi: 10.1111/j.1532-5415.1999.tb01583.x – ident: 12 doi: 10.1016/j.euje.2005.12.014 – ident: 9 doi: 10.1055/s-0041-111499 – ident: 2 doi: 10.1001/jama.2016.3775 – ident: 20 doi: 10.1016/j.jacc.2015.01.039 – ident: 27 doi: 10.1016/j.ajem.2016.06.049 – ident: 4 doi: 10.1111/j.1532-5415.2005.53369.x – ident: 10 doi: 10.1053/j.ajkd.2008.12.034 – ident: 7 doi: 10.1016/j.ahj.2007.11.043 – ident: 22 doi: 10.1016/j.mam.2011.12.002 – ident: 33 doi: 10.1046/j.1365-2141.1996.5101050.x – ident: 30 doi: 10.1177/014860719702100281 |
SSID | ssj0029059 |
Score | 2.2838058 |
Snippet | Background:Antiplatelet therapy (APT) after percutaneous coronary intervention (PCI) prevents ischemic events with increased risk of bleeding. Little is known... Antiplatelet therapy (APT) after percutaneous coronary intervention (PCI) prevents ischemic events with increased risk of bleeding. Little is known about the... BACKGROUNDAntiplatelet therapy (APT) after percutaneous coronary intervention (PCI) prevents ischemic events with increased risk of bleeding. Little is known... |
SourceID | proquest crossref pubmed jstage |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 999 |
SubjectTerms | Aged Aged, 80 and over Albumin Antiplatelet therapy Aspirin - administration & dosage Aspirin - adverse effects Bleeding event Female Humans Male Middle Aged Percutaneous coronary intervention Percutaneous Coronary Intervention - adverse effects Platelet Aggregation Inhibitors - administration & dosage Platelet Aggregation Inhibitors - adverse effects Postoperative Hemorrhage - blood Postoperative Hemorrhage - epidemiology Postoperative Hemorrhage - etiology Pyridines - administration & dosage Pyridines - adverse effects Risk Factors Serum Albumin, Human - metabolism Time Factors |
Title | Decreased Serum Albumin Predicts Bleeding Events in Patients on Antiplatelet Therapy After Percutaneous Coronary Intervention |
URI | https://www.jstage.jst.go.jp/article/circj/81/7/81_CJ-17-0015/_article/-char/en https://www.ncbi.nlm.nih.gov/pubmed/28344205 https://search.proquest.com/docview/1881447436 |
Volume | 81 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
ispartofPNX | Circulation Journal, 2017/06/23, Vol.81(7), pp.999-1005 |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELaqBSEuiDflJSNxQVWWxHES54RKWbRUAnHoSuUUJbZD04UUZVsOK_Fb-SvM2M6DhUosF6uKEzfJfJkZ29_MEPKcS66TQsUeplr3eOQrT7C89Pw8KkuZMBFLQ5D9EB-f8PkyWo5GPwespd22OJTnf40r-R-pwjGQK0bJXkKy3aBwAH6DfKEFCUP7TzJ-Y3y-M_QZdYMr7bjeXtXIq1AVsjRef7HGaXL03USyYZ9NpGp2CaY1kgnB2wThIfcC8wtMpqZq-EfdyB04jhopsjNMc4D0uncDhuTQrZ1VjXR1wLpcFPsSVKCnOwcTjaUvJ8MLHYG0X0vY5l8N1-DT5mx3qnsQrypbartS-rTqELuxBbgXG-hfV82m161Nrlzg2_lu1fa4lQ4b0unUcshjLxU2odOhbo8lHhfMH-pyW_7FYTYZKObUlmFyNj7wTaz3n_aDmSIgEp59fTibe2DB0ansbWXLD7hgQjtiI06pYIzMjJDN5lmA2_uYBOEKw0yEGI2-7DhILPVNNb_u8dw-Oozw8uI9_OY3XV3D1OGz3j8rMt7R4ia54aY1dGoxeouMdH2bXHvviBt3yI8OqtRAlTqo0haqtIUqtVCl2OegSjc1HUKVOqhSA1U6hCptoUqHUL1LTt4eLWbHnqv84cmYsa2nha-VTMKSpVoWoDYEL7gqVSGZBpc4yVMR6CAPZc61CoooFkopHjNdhFxzlYf3yEG9qfUDQkWCFQ1SXeq04CIt4Io4EEoneSFSFUZj8qJ9r9k3m-Al2yfFMXllX3x3pvv03ZkiyBJs-iv6E1Z5AyprTJ61EstAj-PmnH09WSBEwDn48_GY3Lei7P6FYTEc5kcPL3Gvj8h1_IbsauFjcrBtdvoJ-M_b4qnB4C_pL9Du |
link.rule.ids | 315,783,787,4033,27937,27938,27939 |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Decreased+Serum+Albumin+Predicts+Bleeding+Events+in+Patients+on+Antiplatelet+Therapy+After+Percutaneous+Coronary+Intervention&rft.jtitle=Circulation+journal+%3A+official+journal+of+the+Japanese+Circulation+Society&rft.au=Tatami%2C+Yosuke&rft.au=Ishii%2C+Hideki&rft.au=Aoki%2C+Toshijiro&rft.au=Harada%2C+Kazuhiro&rft.date=2017&rft.issn=1346-9843&rft.eissn=1347-4820&rft.volume=81&rft.issue=7&rft.spage=999&rft.epage=1005&rft_id=info:doi/10.1253%2Fcircj.CJ-17-0015&rft.externalDBID=n%2Fa&rft.externalDocID=10_1253_circj_CJ_17_0015 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1346-9843&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1346-9843&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1346-9843&client=summon |